Henry Schein Q3 2026 beat and raised guidance signal recovery, but WAIT thesis holds on execution risk

What happened

Henry Schein reported Q3 2026 sales of $3.5 billion, up 4.0% total and 3.1% internally in local currencies, with GAAP EPS up 26.2% and non-GAAP EPS up 13.0% (or 19.1% excluding current-quarter items). Management raised full-year 2026 guidance, signaling confidence in continued recovery. However, the DeepValue report had maintained a WAIT stance due to elevated execution risk, ongoing restructuring charges through 2027, and regulatory/cyber overhangs. The strong quarter appears to validate the BOLD+1 strategy and margin recovery but does not yet resolve longer-term uncertainties around leadership transition and leverage. Investors should view the results as positive but insufficient to upgrade the thesis without further evidence of durable margin and FCF improvement.

Implication

The raised guidance and strong EPS growth indicate that Henry Schein's recovery from the 2023 cyber incident is gaining traction, and the mix shift toward higher-margin specialty and technology is starting to bear fruit. However, the stock still trades at a premium to DCF (P/E ~24x, EV/EBITDA ~13x), leaving little margin of safety if execution falters. Key risks remain: restructuring charges could escalate, another cyber event could disrupt operations, and the CEO transition alongside KKR's growing influence could alter strategy unpredictably. Investors should watch for sustained improvement in operating margin and free cash flow over the next few quarters, as well as progress on deleveraging from ~2.9x net debt/EBITDA. Until these conditions are met, a disciplined approach suggests waiting for a better entry point or clearer evidence of durable competitive advantages.

Thesis delta

The thesis remains WAIT, but the Q3 beat slightly improves the near-term outlook and reduces downside risk. The improved guidance and EPS growth suggest that the post-cyber recovery is on track, and the specialty/tech mix is contributing. However, the valuation is still not compelling relative to execution risks, so no change to the overall stance.